OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer

被引：1
|
作者：
Park, Junsik [1 ]
Cho, Hyun Woong [2 ]
Lim, Myong Cheol [3 ]
Choi, Chel Hun [4 ]
Lee, Jung-Yun [5 ]
机构：
[1] Soonchunhyang Univ, Coll Med, Bucheon Hosp, Dept Obstet & Gynecol, Bucheon, South Korea
[2] Korea Univ, Coll Med, Guro Hosp, Dept Obstet & Gynecol, Seoul, South Korea
[3] Natl Canc Ctr, Ctr Gynecol Canc, Goyang, South Korea
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea
[5] Yonsei Univ, Coll Med, Inst Womens Life Med Sci, Dept Obstet & Gynecol, Seoul, South Korea
来源：
FUTURE ONCOLOGY | 2024年
基金：
新加坡国家研究基金会;
关键词：
Antibody anti-CA125; indirect immunization; oregovomab; ovarian neoplasms; recurrence; resistant; PEGYLATED LIPOSOMAL DOXORUBICIN; WEEKLY PACLITAXEL; BEVACIZUMAB; MAINTENANCE; OLAPARIB;
D O I：
10.1080/14796694.2024.2357533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A consensus regarding subsequent therapeutic strategies for patients with platinum- and poly (ADP-ribose) polymerase inhibitor (PARPi)-resistant ovarian cancer is lacking. These patients typically receive non-platinum-based chemotherapy; however, survival outcomes remain poor. Compared with chemotherapy alone, combination therapy with novel target agents can provide additional benefits to these patients. Oregovomab, an investigational murine monoclonal antibody against CA-125, has shown promising efficacy in a phase II study in patients with recurrent ovarian cancer. Herein, we described the rationale and design of OPERA/KGOG 3065/APGOT-OV6, a multicenter, investigator-initiated, two-cohort, single-arm phase II trial, aimed at examining the efficacy of oregovomab plus non-platinum-based chemotherapy in patients with PARPi/platinum-resistant ovarian cancer. The primary end point was the objective response rate, according to RECIST 1.1.
引用
收藏
页数：7
相关论文
共 50 条
  • [31] Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
    Mansouri, Anita
    McGregor, Naomi
    Dunn, Rachel
    Dobbie, Sam
    Holmes, Jane
    Collins, Linda
    Nicum, Shibani
    [J]. BMJ OPEN, 2021, 11 (01):
  • [32] Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study
    Keldsen, N
    Havsteen, H
    Vergote, I
    Bertelsen, K
    Jakobsen, A
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 88 (02) : 118 - 122
  • [33] Treosulfan in platinum-resistant ovarian cancer
    Olesen, Katrine Dam
    Larsen, Anja Tolstrup Raedkjaer
    Jensen, Lars Henrik
    Steffensen, Karina Dahl
    Sondergaard, Stine Rauff
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (07) : 1045 - 1051
  • [34] Immunotherapy for platinum-resistant ovarian cancer
    Bogani, Giorgio
    Lopez, Salvatore
    Mantiero, Mara
    Ducceschi, Monika
    Bosio, Sara
    Ruisi, Simona
    Sarpietro, Giuseppe
    Guerrisi, Rocco
    Brusadelli, Claudia
    Dell'Acqua, Andrea
    Di Donato, Violante
    Raspagliesi, Francesco
    [J]. GYNECOLOGIC ONCOLOGY, 2020, 158 (02) : 484 - 488
  • [35] A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
    Oza, Amit M.
    Matulonis, Ursula A.
    Secord, Angeles Alvarez
    Nemunaitis, John
    Roman, Lynda D.
    Blagden, Sarah P.
    Banerjee, Susana
    McGuire, William P.
    Ghamande, Sharad
    Birrer, Michael J.
    Fleming, Gini F.
    Markham, Merry Jennifer
    Hirte, Hal W.
    Provencher, Diane M.
    Basu, Bristi
    Kristeleit, Rebecca
    Armstrong, Deborah K.
    Schwartz, Benjamin
    Braly, Patricia
    Hall, Geoff D.
    Nephew, Kenneth P.
    Jueliger, Simone
    Oganesian, Aram
    Naim, Sue
    Hao, Yong
    Keer, Harold
    Azab, Mohammad
    Matei, Daniela
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (05) : 1009 - 1016
  • [36] Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer - A Gynecologic Oncology Group study
    Plaxe, SC
    Blessing, JA
    Morgan, MA
    Carlson, J
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (01): : 45 - 47
  • [37] PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience
    Agarwal, Amit
    Baghmar, Saphalta
    Dodagoudar, Chandragouda
    Qureshi, Suhail
    Khurana, Aseem
    Vaibhav, Vikas
    Kumar, Guresh
    [J]. JCO GLOBAL ONCOLOGY, 2021, 7 : 506 - 511
  • [38] Platinum-resistant ovarian cancer: Prematurely stopped phase Ⅱ Austrian AGO chemotherapy studies
    Edgar Petru
    Birgit Volgger
    Gerhard Bogner
    Lukas Angleitner-Boubenizek
    Martina Deibl
    Christian Schauer
    Alexander Reinthaller
    Gerhard Wolfram
    Alain Gustave Zeimet
    Christian Marth
    [J]. World Journal of Obstetrics and Gynecology, 2012, (03) : 35 - 39
  • [39] PHASE I/II TRIAL OF GLIF FOR TAXANE/PLATINUM-RESISTANT ENDOMETRIAL CANCER
    Nakagawa, S.
    Ueda, Y.
    Matsuzaki, S.
    Takata, T.
    Kobayashi, E.
    Sawada, K.
    Tomimatsu, T.
    Yoshino, K.
    Kimura, T.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 299 - 299
  • [40] Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.
    Vanderstichele, Adriaan
    Van Nieuwenhuysen, Els
    Han, Sileny
    Concin, Nicole
    Van Gorp, Toon
    Berteloot, Patrick
    Neven, Patrick
    Busschaert, Pieter
    Lambrechts, Diether
    Vergote, Ignace
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345